Transthyretin Amyloidosis (ATTR) is an autosomal dominant hereditary disease that occurs due to deposition of variant TTR (transthyretin) protein in humans. It is mainly characterized into two main types i.e. Hereditary ATTR (hATTR) and Wild-Type (wt) ATTR. The number of Diagnosed Prevalent Population of Transthyretin Amyloidosis was estimated to be around 19,160 cases in 2016. Out of all the diagnosed cases, the number of treatable cases of Transthyretin Amyloidosis was around 9,545 cases in 2016. Region-wise market size analysis of the indication has shown that among 7MM US accounts for the highest market size, followed by EU5 and Japan.
The therapeutic market of Transthyretin Amyloidosis was estimated to be around USD 922 million in 7MM in 2016. Vyndaqel (tafamidis meglumine) by Pfizer is the only approved therapy for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) in adult patients with stage 1 symptomatic Polyneuropathy in Europe and for all stages in Japan. The market is expected to grow significantly with the launch of upcoming drugs: Patisiran (Alnylam Pharmaceuticals) and Inotersen (Ionis Pharmaceuticals Inc.) in 2018 and CRX-1008 (Corino Therapeutics Inc) in 2023.
The report has covered approximately 15 pipeline products out of which around 8 are in the clinical development phase. Detailed historical and forecasted market analysis covering 7MM from 2015-2027 has been provided. Market size by therapy covering 7MM is provided to better understand the market distribution and major players. Historical, as well as the forecasted epidemiology of the disease in the 7MM covering all the major details of the indication, is provided.
Request for sample pages: